Scienion

Boston-based Cellink will acquire the German firm for €40 million in cash and 2,814,032 newly issued shares valued at €40 million at a price of SEK 146.6 per share.

The companies will jointly offer services and equipment solutions for the development, high-volume manufacture, and launch of multiplexed in vitro diagnostics.

The firms will collaborate on creating and co-marketing array technologies for research and clinical diagnostics.

The partners will develop multiplex tests to detect human pathogens in 75 minutes on Grenier's PCR-based Genspeed Test System.

The partners will launch the alliance by developing a colorimetric reader system for multiplexed lateral flow microarrays.

The partners will combine the sciFlexarrayer with Anteo's reagents to improve the functionality and shelf-life of activated glass and polymer slides and other arrays.

QuantuMDx will use Scienion's ultra-low-volume liquid handling technologies in its Q-Poc handheld molecular diagnostic device.